Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2024 | Endocrine therapy and CDK4/6 Inhibitors in high-risk HR+ breast cancer

Simone Nardin, MD, Ospedale Policlinico San Martino, Genoa, Italy, comments endocrine therapy in managing high-risk hormone receptor (HR)-positive breast cancer. While chemotherapy has long been a cornerstone treatment, the emergence of CDK4/6 inhibitors in advanced therapies suggests a potential paradigm shift. These inhibitors may allow for the reduction or even avoidance of chemotherapy in future treatment protocols. Despite this advancement, endocrine therapy is expected to continue playing a crucial role in treatment regimens due to its proven efficacy and superior tolerability relative to other current therapies. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.